Compare · ABT vs OCEA
ABT vs OCEA
Side-by-side comparison of Abbott Laboratories (ABT) and Ocean Biomedical Inc. (OCEA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and OCEA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $179.51B.
- Over the past year, ABT is down 16.4% and OCEA is up 0.0% - OCEA leads by 16.4 points.
- ABT has hit the wire 3 times in the past 4 weeks while OCEA has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for OCEA).
- Company
- Abbott Laboratories
- Ocean Biomedical Inc.
- Price
- $105.58+2.40%
- $0.02-46.75%
- Market cap
- $179.51B
- -
- 1M return
- +13.25%
- +0.00%
- 1Y return
- -16.40%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
Latest OCEA
- SEC Form NT 10-Q filed by Ocean Biomedical Inc.
- SEC Form 25-NSE filed by Ocean Biomedical Inc.
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Ocean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Ocean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form 10-Q filed by Ocean Biomedical Inc.
- Amendment: SEC Form 10-K/A filed by Ocean Biomedical Inc.
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits
- Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value